Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Фаза 3
Идёт, набор закрыт
NCT03765918
| Заболевание | Head and Neck Neoplasms |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Merck Sharp & Dohme LLC |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 714 участн. |
|---|
| Вмешательство | Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2 |
|---|
| Дата начала | 17.12.2018 |
|---|
| Дата завершения | 25.07.2024 |
|---|
| Публикация результатов | 20.08.2025 |
|---|
Кратко
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.
Event-free Survival (EFS)
Up to ~66 months · Months
| Pembrolizumab + Standard of Care (SOC) | 51.8 Months |
|---|
| Standard of Care (SOC) | 30.4 Months |
|---|
| p-value | 0.00411 |
|---|
| Hazard Ratio (HR) | 0.73 (95% CI 0.58–0.92) |
|---|
EFS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
Up to ~66 months · Months
| Pembrolizumab + Standard of Care (SOC) | 59.7 Months |
|---|
| Standard of Care (SOC) | 26.9 Months |
|---|
| p-value | 0.00217 |
|---|
| Hazard Ratio (HR) | 0.66 (95% CI 0.49–0.88) |
|---|
EFS in Participants With PD-L1 CPS ≥1
Up to ~66 months · Months
| Pembrolizumab + Standard of Care (SOC) | 59.7 Months |
|---|
| Standard of Care (SOC) | 29.6 Months |
|---|
| p-value | 0.00140 |
|---|
| Hazard Ratio (HR) | 0.70 (95% CI 0.55–0.89) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.